KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Finished Goods (2016 - 2025)

Historic Finished Goods for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $161.6 million.

  • Halozyme Therapeutics' Finished Goods rose 1259.21% to $161.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.6 million, marking a year-over-year increase of 1259.21%. This contributed to the annual value of $142.9 million for FY2024, which is 10441.01% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Finished Goods stood at $161.6 million, which was up 1259.21% from $164.9 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Finished Goods ranged from a high of $164.9 million in Q2 2025 and a low of $25.8 million during Q4 2021
  • For the 5-year period, Halozyme Therapeutics' Finished Goods averaged around $78.9 million, with its median value being $57.9 million (2023).
  • Over the last 5 years, Halozyme Therapeutics' Finished Goods had its largest YoY gain of 20098.91% in 2021, and its largest YoY loss of 1638.58% in 2021.
  • Over the past 5 years, Halozyme Therapeutics' Finished Goods (Quarter) stood at $25.8 million in 2021, then surged by 78.28% to $46.0 million in 2022, then skyrocketed by 52.12% to $69.9 million in 2023, then surged by 104.41% to $142.9 million in 2024, then rose by 13.04% to $161.6 million in 2025.
  • Its last three reported values are $161.6 million in Q3 2025, $164.9 million for Q2 2025, and $143.2 million during Q1 2025.